In this study, we first reported that KIT mutation predicted a lower response rate and worse PFS in newly diagnosed AML patients treated with VEN/HMA, and it was even more relevant to prognosis than ELN risk stratification. The gene discussed is KIT; the disease is acute myeloid leukemia.